180 Life Sciences granted additional extension by Nasdaq to regain compliance

180 Life Sciences received notice from the Nasdaq Listing Qualifications Panel of The Nasdaq Stock Market that the Hearings Panel has granted the Company’s request for additional time to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Equity Rule. Specifically, the Hearings Panel has agreed to provide the Company until September 20, 2024 to regain compliance with the Equity Rule and to allow the continued listing of the Company’s common stock and warrants on The Nasdaq Stock Market through such date, subject to the Company’s compliance with the Equity Rule on or prior to such date. The Company is currently out of compliance with Listing Rule 5550(b)(1), which requires listed issuers to maintain minimum stockholders’ equity of $2.5 million and does not meet any of the alternative standards in Listing Rule 5550(b). As previously disclosed, on November 15, 2023, the Listing Qualifications department of Nasdaq notified the Company that it did not comply with the Equity Rule and Nasdaq subsequently provided the Company an extension until May 13, 2024, to regain compliance with the Equity Rule.